Trials / Completed
CompletedNCT05700903
Contributions to Hypertension With Androgen Deprivation Therapy
Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- Male
- Age
- 40 Years
- Healthy volunteers
- Accepted
Summary
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gonadotropin Releasing Hormone Agonists (GNRH) | 8 weeks of GnRH agonist |
| DRUG | Androgen receptor (AR) inhibitor | 2 weeks of AR Inhibitor |
| DRUG | Placebo | Placebo tablet and injection |
Timeline
- Start date
- 2023-09-20
- Primary completion
- 2025-07-16
- Completion
- 2025-07-16
- First posted
- 2023-01-26
- Last updated
- 2026-03-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05700903. Inclusion in this directory is not an endorsement.